• Nicolas Boussekey, Raphaël Darmon, Joachim Langlois, Serge Alfandari, Patrick Devos, Agnes Meybeck, Arnaud Chiche, Hugues Georges, and Olivier Leroy.
• Intensive care and infectious disease unit, Tourcoing hospital, rue du Président Coty Tourcoing BP 619, France. nboussekey@ch-tourcoing.fr
• Crit Care. 2010 Jan 1; 14 (2): R40.

IntroductionAcute kidney injury (AKI) in the ICU is associated with poorer prognosis. Hydroxyethylstarch (HES) solutions are fluid resuscitation colloids frequently used in the ICU with controversial nephrotoxic adverse effects. Our study objective was to evaluate HES impact on renal function and organ failures.MethodsThis observational retrospective study included 363 patients hospitalized for more than 72 hours in our ICU. A hundred and sixty eight patients received HES during their stay and 195 did not. We recorded patients' baseline characteristics on admission and type and volume of fluid resuscitation during the first 3 weeks of ICU stay. We also noted the evolution of urine output, the risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function and end-stage kidney disease (RIFLE) classification and sepsis related organ failure assessment (SOFA) score over 3 weeks.ResultsPatients in the HES group were more severely ill on admission but AKI incidence was similar, as well as ICU mortality. The evolution of urine output (P = 0.74), RIFLE classification (P = 0.44) and SOFA score (P = 0.23) was not different. However, HES volumes administered were low (763+/-593 ml during the first 48 hours).ConclusionsVolume expansion with low volume HES 130 kDa/0.4 was not associated with AKI.

21 keywords...

hide…